Flags with the slogans of the Danish pharmaceutical maker, NOVO Nordisk, the diabetes maker and the OzemPic and Wegov weightmaker are pictures while the company provides the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.
Mads Claus Rasmussen | AFP | Gety pictures
Copenhagen, Denmark – Obesity Antarctic Novo Nordsk He said on Thursday that the outbreak of the vehicle's drug industry in the United States was harmful to sales and woven, and he warned that she was considering taking legal measures against companies that believe that they violate their intellectual property.
US pharmacies were allowed to create legal copies of Wegovy and Diabros in Novo, both chemically known as Semaglutide, under drug and drug administration.
The FDA (FDA) announced last month that the shortage has ended, while giving compound pharmacies until May 22 to stop selling copies of the drug. It follows the lift a A similar deficiency sign On a competitor Elie Lily Zepbound in December.
CEO Lars Fergard Juerginson said the efforts to support the width of the famous weight loss drug led to the removal of the drug from the drug deficiency list.
“Given the significant growth of the double in the United States, it seems to affect the absorption of medical prescriptions in Wigrii in 2025 so far,” Fruegaard Jentsensen told the shareholders at the company's annual meeting in Copenhagen, Denmark.
He added: “We are also taking legal measures against these compounds because we believe that they are violating our IP address (intellectual property), and in this way, they harm our actions.”
This discussion sparked a legal battle between two drugs and drugs ’vehicles trade in the Association of Foreign Sources (Offa), which seeks to maintain rights in the production of profitable medicines.
Ufa It is called a name The FDA decision to announce the end of the “reckless and arbitrary” deficiency, adding that “patients will be deprived of a vital treatment for type 2 diabetes, obesity, cardiovascular diseases and other serious medical conditions.”
Request for complex obesity medications, including TELHEATH HIMS & HERS, may fade amid high costs and short offerings of brand treatments. Such products The Food and Drug Administration has not been approvedHowever, in the sense that the agency does not review it for safety, event or quality before marketing it.
FRUERGAARD JUNGENSEN said on Thursday that the Novo Nordisk analysis had discovered “impurities and even banned products” in some compound products, without naming any specific producers.
“This is not Smaglutide,” he said, referring to complex alternatives. “There is only one second, and patients must check the products before they pump them.”
The FBI follows warning In February, fake weight loss drugs that claim to contain Smaglutide were found to include “vehicle mixtures of unknown drugs that do not contain semaglutide, high -level drugs, unsafe or unknown drugs.”
Fruergaard J OffGensen said he is optimistic that patients will return to the treatments of Wegovy and OzemPic brands with an increasingly available offer. Earlier this month, a new Danish pharmaceutical company launched Online pharmacy directly to the consumer Submit Wegov at less than half of the price trying to attract users from copying a cheaper vehicle.
“We have expanded the width range, so we are now outside the food and drug management deficiency menu. I hope many of these patients will return to Novo Nordisk,” said Fruegaard J Offgensen.
Novo Nordisk seeks to reassure investors from the ongoing initiative in the market amid the increasing competition and a series of experiments of disappointing obesity for hopes that were beaten at the company's high share.
Last month, the company I mentioned A net profit is better than expected in the fourth quarter amid the high demand for obesity medications in Wegovy, but a slight slowdown in sales for 2025.
Novo Nordisk closed by 3.8 % on Thursday after AGM.
